SVB Wealth LLC Takes $404,000 Position in Halozyme Therapeutics, Inc. $HALO

SVB Wealth LLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 5,162 shares of the biopharmaceutical company’s stock, valued at approximately $404,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Measured Wealth Private Client Group LLC boosted its position in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 124 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares during the period. MidFirst Bank bought a new position in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $28,000. Finally, Quantbot Technologies LP purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $30,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $79,987,320.40. This represents a 2.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director directly owned 14,462 shares in the company, valued at $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 32,478 shares of company stock worth $3,076,604 over the last three months. 2.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on HALO. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Citizens Jmp increased their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. UBS Group restated a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $91.20.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $107.00 on Friday. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The business’s 50 day moving average price is $93.18 and its 200-day moving average price is $76.75. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $111.15. The stock has a market cap of $12.14 billion, a P/E ratio of 31.94, a P/E/G ratio of 0.42 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.98 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.